Aortic Disease and Treatment Approaches / Cardiac Valve Diseases and Treatments / Congenital Heart Disease Studies · Journal article

New ESC/EACTS guidelines for the management of aortic valve disease: key takeaways and implications of long-term TAVR results based on recent explant and redo-TAVR registry outcomes

Journal of Cardiothoracic Surgery · August 6, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This narrative review summarizes the 2025 ESC/EACTS guideline shift toward earlier and broader TAVR use in aortic valve disease, informed by registry data showing reintervention rates of 0.3–1.7% at 8 years and superior short-term survival with redo-TAVR versus explantation. The evidence highlights structural valve deterioration, leaflet thrombosis, and endocarditis as dominant failure modes, requiring long-term surveillance and refined patient selection in younger cohorts.

What was studied

Narrative review integrating guideline statements and observational registries. Patients with aortic stenosis and aortic regurgitation; registry data from EXPLANT-TAVR, EXPLANTORREDO-TAVR, and FRANCE 2/FRANCE TAVI (2020–2025).. Intervention: TAVR; redo-TAVR; explantation.. Compared with: Redo-TAVR versus explantation for short-term mortality comparison..

Key findings

Reintervention rates 0.3–1.7% at 8 years across EXPLANT-TAVR, EXPLANTORREDO-TAVR and FRANCE 2/FRANCE TAVI registries Redo-TAVR 30-day mortality 1.5–6.2% versus explantation 11.9–13.6%, favouring redo approach for short-term survival Structural valve deterioration, leaflet thrombosis, and endocarditis identified as predominant TAVR failure causes

Safety

Redo-TAVR 30-day mortality 1.5–6.2% versus explantation 11.9–13.6%, favouring redo approach for short-term survival

Who this may help

Clinicians should use this to inform shared decision-making with Heart Teams, balancing the expanded indications for earlier TAVR intervention (as per 2025 ESC/EACTS guidelines) against the long-term reintervention risk and durability concerns in younger patients. Structured surveillance for structural valve deterioration and thrombosis, and readiness for redo procedures, are warranted.

Plain-language summary

A narrative review synthesizing guideline updates and registry evidence on TAVR durability and reintervention; informs clinical decision-making but lacks original comparative effectiveness data.

Study design

As stated by the source record.

MethodsNarrative review integrating guideline statements and observational registries

PopulationPatients with aortic stenosis and aortic regurgitation; registry data from EXPLANT-TAVR, EXPLANTORREDO-TAVR, and FRANCE 2/FRANCE TAVI (2020–2025).

InterventionTAVR; redo-TAVR; explantation.

ComparatorRedo-TAVR versus explantation for short-term mortality comparison.

Reported figures

Quoted from the source exactly as published.

Reintervention rate at 8 years0.3–1.7%

30-day mortality after redo-TAVR1.5–6.2%

30-day mortality after explantation11.9–13.6%

Clinical bottom line

Caveats

Registry reintervention rates reported as ranges without individual study sample sizes or confidence intervals
Failure mode frequencies (SVD, thrombosis, endocarditis) not quantified; relative proportions and absolute rates not given
Narrative review format; no systematic literature search, GRADE assessment, or meta-analysis methodology disclosed
Specific eligibility criteria, follow-up durations, and baseline characteristics of registry cohorts not detailed in abstract

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Narrative review integrating guideline statements and observational registries; no original RCT or primary data.

Directness

moderate

Directly addresses TAVR durability and reintervention in clinical practice; registry data are real-world outcomes.

Consistency

moderate

Multiple registries cited; reintervention rates reported across sources, but SVD and thrombosis as failure causes not quantified.

Risk of bias

limited

Observational registries subject to selection and reporting bias; no formal quality assessment provided.

Sample adequacy

moderate

Registry data span multiple centres and cohorts (2020–2025); specific denominator and population breakdowns not detailed.

Source abstract

Abstract Background The 2025 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for valvular heart disease represent a pivotal update, emphasizing earlier intervention for aortic stenosis (AS) and broader indications for transcatheter aortic valve replacement (TAVR). These changes are driven by randomized trial data demonstrating TAVR’s safety in lower-risk patients. However, as TAVR expands to younger cohorts, long-term durability remains a concern. Main body This narrative review examines key guideline updates for aortic valve disease, focusing on aortic stenosis (AS) and aortic regurgitation (AR), and integrates insights from recent registries (2020–2025) on TAVR explantation and redo-TAVR outcomes. Data from the EXPLANT-TAVR, EXPLANTORREDO-TAVR and FRANCE 2/FRANCE TAVI registries reveal reintervention rates of 0.3–1.7% at 8 years, with redo-TAVR offering superior short-term survival (30-day mortality 1.5–6.2%) compared to explantation (11.9–13.6%). Structural valve deterioration (SVD), leaflet thrombosis, and endocarditis predominate failure causes, underscoring the need for lifetime management strategies. Conclusion Implications include refined patient selection, enhanced imaging surveillance, and Heart Team-driven decisions to balance procedural benefits against reintervention risks.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Aortic Disease and Treatment ApproachesCardiac Valve Diseases and TreatmentsCongenital Heart Disease StudiesSaptarshi Paul